CR20150405A - Anticuerpos anti-il-17a y su uso en el tratamiento de transtornos autoinmunes e inflamatorios - Google Patents
Anticuerpos anti-il-17a y su uso en el tratamiento de transtornos autoinmunes e inflamatoriosInfo
- Publication number
- CR20150405A CR20150405A CR20150405A CR20150405A CR20150405A CR 20150405 A CR20150405 A CR 20150405A CR 20150405 A CR20150405 A CR 20150405A CR 20150405 A CR20150405 A CR 20150405A CR 20150405 A CR20150405 A CR 20150405A
- Authority
- CR
- Costa Rica
- Prior art keywords
- antibodies
- autoimmune
- treatment
- inflammatory disorders
- cytokine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Microbiology (AREA)
- Mycology (AREA)
Abstract
La presente descripción se refiere a los anticuerpos y las proteínas que comprenden unaporción de unión a antígeno de los mismos que se unen específicamente a IL-17A de citoquinaspro-inflamatorias.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361762406P | 2013-02-08 | 2013-02-08 | |
PCT/IB2014/058854 WO2014122613A1 (en) | 2013-02-08 | 2014-02-07 | Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20150405A true CR20150405A (es) | 2015-09-28 |
Family
ID=50239702
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20150405A CR20150405A (es) | 2013-02-08 | 2015-08-06 | Anticuerpos anti-il-17a y su uso en el tratamiento de transtornos autoinmunes e inflamatorios |
Country Status (39)
Country | Link |
---|---|
US (5) | US9193788B2 (es) |
EP (2) | EP3656786A1 (es) |
JP (2) | JP6084708B2 (es) |
KR (1) | KR101877109B1 (es) |
CN (1) | CN105073775B (es) |
AP (1) | AP2015008584A0 (es) |
AR (1) | AR095193A1 (es) |
AU (1) | AU2014213599C1 (es) |
BR (1) | BR112015017338B1 (es) |
CA (2) | CA2897682C (es) |
CL (1) | CL2015001941A1 (es) |
CR (1) | CR20150405A (es) |
CU (1) | CU24300B1 (es) |
CY (1) | CY1122322T1 (es) |
DK (1) | DK2953969T3 (es) |
EA (1) | EA031537B1 (es) |
ES (1) | ES2758473T3 (es) |
GT (1) | GT201500220A (es) |
HK (1) | HK1211604A1 (es) |
HR (1) | HRP20192076T1 (es) |
HU (1) | HUE047119T2 (es) |
IL (1) | IL240135B (es) |
JO (1) | JO3785B1 (es) |
LT (1) | LT2953969T (es) |
MA (1) | MA38322B1 (es) |
MX (1) | MX371052B (es) |
PE (1) | PE20151290A1 (es) |
PH (1) | PH12015501713A1 (es) |
PL (1) | PL2953969T3 (es) |
PT (1) | PT2953969T (es) |
RS (1) | RS59625B1 (es) |
SG (1) | SG11201505330QA (es) |
SI (1) | SI2953969T1 (es) |
SV (1) | SV2015005019A (es) |
TN (1) | TN2015000309A1 (es) |
TW (1) | TWI632159B (es) |
UA (1) | UA117575C2 (es) |
UY (1) | UY35315A (es) |
WO (1) | WO2014122613A1 (es) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ603570A (en) | 2010-05-20 | 2014-12-24 | Ablynx Nv | Biological materials related to her3 |
UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
CU24300B1 (es) * | 2013-02-08 | 2017-12-08 | Novartis Ag | Anticuerpos anti-il-17a útiles en el tratamiento de trastornos autoinmunes e inflamatorios |
US11548940B2 (en) | 2014-05-15 | 2023-01-10 | Rani Therapeutics, Llc | Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
EP3161001A2 (en) * | 2014-06-25 | 2017-05-03 | Novartis AG | Antibodies specific for il-17a fused to hyaluronan binding peptide tags |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
CR20170143A (es) | 2014-10-14 | 2017-06-19 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas |
CN107407677B (zh) * | 2015-01-28 | 2020-07-17 | 豪夫迈·罗氏有限公司 | 多发性硬化的基因表达标志和治疗 |
EP4378957A2 (en) | 2015-07-29 | 2024-06-05 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
DK3317301T3 (da) | 2015-07-29 | 2021-06-28 | Immutep Sas | Kombinationsterapier omfattende antistofmolekyler mod lag-3 |
WO2017019897A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
CN106474470B (zh) * | 2015-08-28 | 2020-05-22 | 江苏恒瑞医药股份有限公司 | 一种抗il-17a抗体的组合物 |
JP6931648B2 (ja) | 2015-10-27 | 2021-09-08 | ユーシービー バイオファルマ エスアールエル | 抗il−17a/f抗体を用いた治療方法 |
CN108495651A (zh) | 2015-12-17 | 2018-09-04 | 诺华股份有限公司 | 抗pd-1的抗体分子及其用途 |
US11472877B2 (en) * | 2016-03-04 | 2022-10-18 | Alector Llc | Anti-TREM1 antibodies and methods of use thereof |
CN107488227A (zh) * | 2016-06-12 | 2017-12-19 | 三生国健药业(上海)股份有限公司 | 抗人白细胞介素‑17a单克隆抗体、其制备方法和应用 |
WO2017221174A1 (en) | 2016-06-22 | 2017-12-28 | Novartis Ag | Methods of treating vitiligo using interleukin-17 (il-17) antibodies |
GB201612043D0 (en) * | 2016-07-11 | 2016-08-24 | Crescendo Biologics Ltd | Composition for treatment of disorders |
WO2018015880A1 (en) | 2016-07-19 | 2018-01-25 | Novartis Ag | Methods of treating new-onset plaque type psoriasis using il-17 antagonists |
IL265350B1 (en) * | 2016-09-14 | 2024-06-01 | Beijing hanmi pharm co ltd | An antibody that specifically binds to IL-17A and its functional fragment |
WO2018096467A1 (en) | 2016-11-28 | 2018-05-31 | Novartis Ag | Methods of treating acne using interleukin-17 (il-17) antagonists |
WO2018158741A1 (en) | 2017-03-03 | 2018-09-07 | Novartis Ag | Psoriasis disease modification following long-term treatment with an il-17 antagonist |
WO2018161340A1 (en) * | 2017-03-10 | 2018-09-13 | X-Kang United Biopharmaceutical Science & Technology Co., Ltd. | Monoclonal antibody against both il-17a and il-17f and use of the same |
TW201842933A (zh) * | 2017-05-05 | 2018-12-16 | 瑞士商諾華公司 | 使用il-17拮抗劑選擇性治療氣喘的方法 |
CN108359011B (zh) | 2017-07-21 | 2019-06-25 | 华博生物医药技术(上海)有限公司 | 靶向于白介素17a的抗体、其制备方法和应用 |
CN107522783B (zh) * | 2017-09-30 | 2020-07-07 | 华博生物医药技术(上海)有限公司 | 一种抗白介素17a的抗体、其制备方法和应用 |
EP3703819A1 (en) | 2017-11-02 | 2020-09-09 | Novartis AG | Method of treating tendinopathy using interleukin-17 (il-17) antagonists |
KR102048475B1 (ko) * | 2017-11-10 | 2019-11-26 | 주식회사 와이바이오로직스 | IL-17A (Interleukin-17A)에 특이적으로 결합하는 항체 및 이의 용도 |
US20200277369A1 (en) | 2017-11-20 | 2020-09-03 | Novartis Ag | Method of treating hidradentitis suppurativa with il-17 antagonists |
AU2018375738A1 (en) | 2017-11-30 | 2020-06-11 | Novartis Ag | BCMA-targeting chimeric antigen receptor, and uses thereof |
WO2019163945A1 (ja) | 2018-02-22 | 2019-08-29 | 学校法人東海大学 | Il-17a活性阻害剤およびその用途 |
JP2021519589A (ja) * | 2018-03-29 | 2021-08-12 | アールイーエムディー バイオセラピューティクス,インコーポレイテッドREMD Biotherapeutics,Inc | インターロイキン17a(il−17a)に結合する抗体を用いた自己免疫障害及び炎症障害の治療 |
KR20210011919A (ko) | 2018-04-17 | 2021-02-02 | 셀덱스 쎄라퓨틱스, 인크. | 항-cd27 항체 및 항-pd-l1 항체 및 이중특이적 작제물 |
CN108640991B (zh) * | 2018-05-17 | 2019-09-27 | 江苏荃信生物医药有限公司 | 抗人白介素17a单克隆抗体及其应用 |
KR20210016390A (ko) | 2018-06-01 | 2021-02-15 | 노파르티스 아게 | Bcma에 대한 결합 분자 및 이의 용도 |
GB201820165D0 (en) * | 2018-12-11 | 2019-01-23 | Ucb Biopharma Sprl | Therapeutic agents |
CN111303283A (zh) * | 2018-12-12 | 2020-06-19 | 上海君实生物医药科技股份有限公司 | 抗il-17a抗体及其应用 |
EP3689907A1 (en) | 2019-01-31 | 2020-08-05 | Numab Therapeutics AG | Antibodies targeting il-17a and methods of use thereof |
KR20210122243A (ko) | 2019-01-31 | 2021-10-08 | 누맙 세러퓨틱스 아게 | TNFα 및 IL-17A에 대한 특이성을 가지는 다중 특이적 항체, IL-17A를 표적화하는 항체, 그리고 이의 사용 방법 |
WO2021018035A1 (zh) * | 2019-07-26 | 2021-02-04 | 神州细胞工程有限公司 | 人源化抗il17a抗体及其应用 |
CN114127108A (zh) * | 2019-07-30 | 2022-03-01 | 江苏恒瑞医药股份有限公司 | Il-17拮抗剂治疗自身免疫疾病的方法 |
EP4061418A1 (en) | 2019-11-19 | 2022-09-28 | Novartis AG | Methods of treating lupus nephritis using interleukin-17 (il-17) antagonists |
IL293354A (en) | 2019-12-06 | 2022-07-01 | Novartis Ag | Methods for treating flatulence using interleukin-17 (il-17) antagonists |
KR20220119090A (ko) * | 2019-12-20 | 2022-08-26 | 안토스 테라퓨틱스, 인크. | 인자 XI/XIa 항체에 대한 제약 제제 및 투여 요법 |
CN115812079A (zh) | 2020-06-23 | 2023-03-17 | 诺华股份有限公司 | 使用白细胞介素-17(il-17)拮抗剂治疗甲状腺眼病和格雷夫斯眼眶病的方法 |
WO2022032592A1 (en) * | 2020-08-13 | 2022-02-17 | Tsinghua University | Interleukin-17d and cd93 as a new cytokine-receptor pair in the immune system |
UY39484A (es) | 2020-11-02 | 2022-06-30 | Novartis Ag | Inhibidores de interleucina-17 |
WO2022097060A1 (en) | 2020-11-06 | 2022-05-12 | Novartis Ag | Cd19 binding molecules and uses thereof |
WO2023035272A1 (zh) * | 2021-09-13 | 2023-03-16 | 深圳华普药物研发有限公司 | 一种il17抗体及其制备方法和应用 |
CN116496394A (zh) * | 2022-01-26 | 2023-07-28 | 东莞市朋志生物科技有限公司 | 抗s100蛋白的抗体、检测s100蛋白的试剂和试剂盒 |
WO2023223211A1 (en) | 2022-05-16 | 2023-11-23 | Novartis Ag | Methods of treating giant cell arteritis using interleukin-17 (il-17) antagonists |
WO2023223263A1 (en) | 2022-05-18 | 2023-11-23 | Novartis Ag | Methods of selectively treating tendinopathy using interleukin-17 (il-17) antagonists |
WO2024059497A1 (en) * | 2022-09-12 | 2024-03-21 | Albert Einstein College Of Medicine | Monoclonal antibodies to arabinomannan (am), groel2, and lprg and methods of use |
Family Cites Families (116)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
SE434680B (sv) | 1983-01-21 | 1984-08-06 | Karl Arne Lundblad | Anvendning av en saltlosning av monoklonala antikroppar med relativt hog salthalt vid blodgruppsbestemning |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
EP0318554B2 (en) | 1987-05-21 | 2005-01-12 | Micromet AG | Targeted multifunctional proteins |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
WO1990006952A1 (en) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
DK0463151T3 (da) | 1990-01-12 | 1996-07-01 | Cell Genesys Inc | Frembringelse af xenogene antistoffer |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
DE69133476T2 (de) | 1990-08-29 | 2006-01-05 | GenPharm International, Inc., Palo Alto | Transgene Mäuse fähig zur Produktion heterologer Antikörper |
WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
ES2202310T3 (es) | 1991-12-13 | 2004-04-01 | Xoma Corporation | Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos. |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
AU4116793A (en) | 1992-04-24 | 1993-11-29 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
DE69330523T4 (de) | 1992-08-21 | 2012-08-23 | Vrije Universiteit Brussel | Immunoglobuline ohne leichte ketten |
AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
GB2339430A (en) | 1997-05-21 | 2000-01-26 | Biovation Ltd | Method for the production of non-immunogenic proteins |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
DE69942021D1 (de) | 1998-04-20 | 2010-04-01 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
PL220113B1 (pl) | 1999-01-15 | 2015-08-31 | Genentech Inc | Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc |
EP2270150B2 (en) | 1999-04-09 | 2019-08-07 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
DE19932688B4 (de) | 1999-07-13 | 2009-10-08 | Scil Proteins Gmbh | Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen |
EP1792991A1 (en) | 1999-08-24 | 2007-06-06 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
US7943129B2 (en) | 2000-05-26 | 2011-05-17 | National Research Council Of Canada | Single-domain brain-targeting antibody fragments derived from llama antibodies |
CA2412701A1 (en) | 2000-06-28 | 2002-01-03 | Glycofi, Inc. | Methods for producing modified glycoproteins |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US7041870B2 (en) | 2000-11-30 | 2006-05-09 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
US20040175756A1 (en) | 2001-04-26 | 2004-09-09 | Avidia Research Institute | Methods for using combinatorial libraries of monomer domains |
US20050048512A1 (en) | 2001-04-26 | 2005-03-03 | Avidia Research Institute | Combinatorial libraries of monomer domains |
US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
EP1421203A4 (en) | 2001-05-17 | 2005-06-01 | Diversa Corp | NEW ANTIGEN-BINDING MOLECULES FOR THERAPEUTIC, DIAGNOSTIC, PROPHYLACTIC, ENZYMATIC, INDUSTRIAL AND AGRICULTURAL APPLICATIONS AND METHOD FOR THE PRODUCTION AND SCREENING THEREOF |
WO2003035835A2 (en) | 2001-10-25 | 2003-05-01 | Genentech, Inc. | Glycoprotein compositions |
AU2003217912A1 (en) | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
DE10324447A1 (de) | 2003-05-28 | 2004-12-30 | Scil Proteins Gmbh | Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin |
EP1761561B1 (en) | 2004-01-20 | 2015-08-26 | KaloBios Pharmaceuticals, Inc. | Antibody specificity transfer using minimal essential binding determinants |
US20060008844A1 (en) | 2004-06-17 | 2006-01-12 | Avidia Research Institute | c-Met kinase binding proteins |
GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
US20060286103A1 (en) | 2005-06-15 | 2006-12-21 | Parag Kolhe | Stable antibody formulation |
RS63964B1 (sr) | 2005-08-23 | 2023-03-31 | Univ Pennsylvania | Rnk koja sadrži modifikovane nukleozide i postupci za njenu upotrebu |
DK1963368T6 (da) * | 2005-12-13 | 2020-06-29 | Lilly Co Eli | Anti-il-17-antistoffer |
EP1987067A4 (en) | 2006-02-15 | 2012-01-25 | Imclone Llc | ANTIBODY FORMULATION |
AU2007226627B2 (en) | 2006-03-10 | 2012-09-20 | Zymogenetics, Inc. | Antibodies that bind both IL-17A and IL-17F and methods of using the same |
US7910703B2 (en) * | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
TW200815469A (en) * | 2006-06-23 | 2008-04-01 | Astrazeneca Ab | Compounds |
EP2046835B1 (en) | 2006-08-11 | 2011-10-26 | Schering Corporation | Antibodies to il-17a |
AU2007352412B2 (en) | 2007-04-27 | 2013-05-16 | Zymogenetics, Inc. | Antibodies that bind both IL-17A and IL-17F and methods of using the same |
ES2493042T3 (es) * | 2008-09-29 | 2014-09-11 | Roche Glycart Ag | Anticuerpos contra la IL-17 humana y usos de los mismos |
JP5836807B2 (ja) * | 2009-03-05 | 2015-12-24 | アッヴィ・インコーポレイテッド | Il−17結合タンパク質 |
CN104974250A (zh) | 2009-05-05 | 2015-10-14 | 诺维莫尼公司 | 抗il-17f抗体及其使用方法 |
CN102905727B (zh) * | 2009-10-30 | 2016-12-07 | 詹森生物科技公司 | Il-17a拮抗剂 |
GB201100282D0 (en) | 2011-01-07 | 2011-02-23 | Ucb Pharma Sa | Biological methods |
WO2013090186A1 (en) | 2011-12-14 | 2013-06-20 | modeRNA Therapeutics | Modified nucleic acids, and acute care uses thereof |
CU24300B1 (es) * | 2013-02-08 | 2017-12-08 | Novartis Ag | Anticuerpos anti-il-17a útiles en el tratamiento de trastornos autoinmunes e inflamatorios |
-
2014
- 2014-02-07 CU CUP2015000079A patent/CU24300B1/es unknown
- 2014-02-07 AP AP2015008584A patent/AP2015008584A0/xx unknown
- 2014-02-07 EA EA201591462A patent/EA031537B1/ru not_active IP Right Cessation
- 2014-02-07 AR ARP140100403A patent/AR095193A1/es active IP Right Grant
- 2014-02-07 JP JP2015556599A patent/JP6084708B2/ja active Active
- 2014-02-07 MA MA38322A patent/MA38322B1/fr unknown
- 2014-02-07 TW TW103104172A patent/TWI632159B/zh active
- 2014-02-07 SI SI201431415T patent/SI2953969T1/sl unknown
- 2014-02-07 HU HUE14708950A patent/HUE047119T2/hu unknown
- 2014-02-07 LT LT14708950T patent/LT2953969T/lt unknown
- 2014-02-07 ES ES14708950T patent/ES2758473T3/es active Active
- 2014-02-07 CN CN201480007944.XA patent/CN105073775B/zh active Active
- 2014-02-07 SG SG11201505330QA patent/SG11201505330QA/en unknown
- 2014-02-07 PL PL14708950T patent/PL2953969T3/pl unknown
- 2014-02-07 EP EP19193872.9A patent/EP3656786A1/en active Pending
- 2014-02-07 UY UY0001035315A patent/UY35315A/es active IP Right Grant
- 2014-02-07 KR KR1020157023999A patent/KR101877109B1/ko active IP Right Grant
- 2014-02-07 CA CA2897682A patent/CA2897682C/en active Active
- 2014-02-07 US US14/174,942 patent/US9193788B2/en active Active
- 2014-02-07 RS RS20191511A patent/RS59625B1/sr unknown
- 2014-02-07 PT PT147089502T patent/PT2953969T/pt unknown
- 2014-02-07 EP EP14708950.2A patent/EP2953969B1/en active Active
- 2014-02-07 DK DK14708950T patent/DK2953969T3/da active
- 2014-02-07 BR BR112015017338-1A patent/BR112015017338B1/pt active IP Right Grant
- 2014-02-07 PE PE2015001605A patent/PE20151290A1/es unknown
- 2014-02-07 WO PCT/IB2014/058854 patent/WO2014122613A1/en active Application Filing
- 2014-02-07 AU AU2014213599A patent/AU2014213599C1/en active Active
- 2014-02-07 MX MX2015010248A patent/MX371052B/es active IP Right Grant
- 2014-02-07 CA CA3185317A patent/CA3185317A1/en active Pending
- 2014-02-09 JO JOP/2014/0029A patent/JO3785B1/ar active
- 2014-07-02 UA UAA201506581A patent/UA117575C2/uk unknown
-
2015
- 2015-07-08 CL CL2015001941A patent/CL2015001941A1/es unknown
- 2015-07-16 TN TN2015000309A patent/TN2015000309A1/en unknown
- 2015-07-23 IL IL240135A patent/IL240135B/en active IP Right Grant
- 2015-07-28 SV SV2015005019A patent/SV2015005019A/es unknown
- 2015-08-03 PH PH12015501713A patent/PH12015501713A1/en unknown
- 2015-08-06 CR CR20150405A patent/CR20150405A/es unknown
- 2015-08-11 GT GT201500220A patent/GT201500220A/es unknown
- 2015-09-21 US US14/859,872 patent/US9650439B2/en active Active
- 2015-12-16 HK HK15112401.1A patent/HK1211604A1/xx unknown
-
2016
- 2016-07-20 JP JP2016142281A patent/JP6266710B2/ja active Active
-
2017
- 2017-03-22 US US15/466,128 patent/US9938342B2/en active Active
-
2018
- 2018-02-27 US US15/906,446 patent/US10683349B2/en active Active
-
2019
- 2019-11-18 HR HRP20192076TT patent/HRP20192076T1/hr unknown
- 2019-11-26 CY CY20191101237T patent/CY1122322T1/el unknown
-
2020
- 2020-04-30 US US16/862,776 patent/US20200299379A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20150405A (es) | Anticuerpos anti-il-17a y su uso en el tratamiento de transtornos autoinmunes e inflamatorios | |
CL2018000479A1 (es) | Linfoopeitina strimal tomica (tslp) - anticuerpos de union y metodos de uso de los anticuerpos | |
CY1120849T1 (el) | Αντισωμα που συνδεεται σε ανθρωπινο cd3 | |
CO2019013935A2 (es) | Anticuerpos que se unen específicamente a pd-1 y métodos de uso | |
CL2016001102A1 (es) | Anticuerpos anti-claudina novedosos y métodos de uso. | |
CR20150618A (es) | Anticuerpos receptores de antitransferina y métodos de uso | |
CU24427B1 (es) | Moléculas de anticuerpo que se unen a tim-3 | |
PE20210648A1 (es) | Anticuerpos anti-cd3 y metodos de uso | |
BR112016000106A2 (pt) | anticorpos c1q do fator anti-complemento e usos dos mesmos | |
CL2016000460A1 (es) | Proteínas de unión al antígeno gitr | |
CL2015002562A1 (es) | Anticuerpos e inmunoconjugados anti-b7-h4 | |
CL2015000582A1 (es) | Anticuerpos anti-mcam y métodos asociados de uso | |
CR20150329A (es) | Inmunoglobulinas heterodiméricas | |
BR112017011932A2 (pt) | ?anticorpos direcionados a receptor acoplado a proteína g e métodos de uso? | |
CL2016001432A1 (es) | Nuevos anticuerpos anti-dpep3 y métodos de uso | |
CY1123493T1 (el) | Παραγων συνδεσης il-17a και χρησεις αυτου | |
BR112015021521A2 (pt) | anticorpos anti-crth2 e métodos para seu uso | |
DK2970460T3 (da) | Anti-IL-33-antistoffer og anvendelser deraf | |
EA201600473A1 (ru) | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К Tau(PS422) И СПОСОБЫ ПРИМЕНЕНИЯ | |
BR112013017951A2 (pt) | moléculas de anticorpo que ligam il-17a e il-17f | |
CL2015002724A1 (es) | Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23 | |
CR20140382A (es) | Anticuerpos anti-lrp5 y metodos de uso | |
PE20151925A1 (es) | Anticuerpos anti-igf-1r con abolicion de la union al fcrn y su utilizacion en el tratamiento de enfermedades oculares vasculares | |
CY1123519T1 (el) | Ανθρωπινα μονοκλωνικα αντισωματα εξουδετερωσης il-ß | |
MX2016005854A (es) | Anticuerpo anti-her3 alosterico de la neuregulina. |